ASCO 2024 Poster for Trial #22-14

Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

Click the above link to view the abstract and video; a login is required to view the video.

Click here to view the ASCO 2024 Presentation for Trial 22-14.

Related Abstracts

Discover more abstracts for our trials.

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider

Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

Sep 24, 2024

Dr. Reva Schneider

First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients

Sep 24, 2024

Dr. Douglas Orr
See All Posts